The next GLP-1 battleground may not be the molecule. It may be the missing decision layer around the patient.Your blog post

In September 2026, the WHO published a global mapping of GLP-1 manufacturers, reflecting how rapidly the ecosystem is expanding. Meanwhile, oral GLP-1 programs and next-generation combinations are advancing across Type 2 diabetes, obesity and metabolic health. But one commercial question remains difficult to connect: What happens between GLP-1 demand and the real-world nutrition decision? Patients search for protein, meal planning, glucose control and nutrition support. HCPs discuss nutrition, CGM readings, weight, adherence and intervention. Telehealth creates another layer of clinical interaction. Yet conventional datasets often measure these signals separately. Apex Global HCP & Telehealth Radar connects them. 40 variables across HCP universe, specialty, geography, digital intent, GLP-1 nutrition signals, CGM behavior, telehealth encounters, patient questions, HCP recommendation behavior and competitive signals. The objective: Find the Decision Gap before it appears in sales. For pharma, medtech, diabetes care, nutrition and digital-health leaders, this can reveal where patient demand is accelerating, HCP intervention is lagging, and new commercial opportunities are forming. If your strategy involves Type 2 diabetes, GLP-1, CGM, telehealth or metabolic health—let’s compare signals. info@apxmetrics.com I www.apxmetrics.com